Abstract Traditional management strategies for Peyronie’s disease, largely monotherapeutic and stage-dependent, have produced inconsistent outcomes and rarely address the underlying biology of fibrosis. Based on existing knowledge, a multimodal novel concept, the 3Ts Protocol, is presented, involving Tadalafil daily, Tunneling with intralesional biologics, and daily Traction therapy. It introduces a comprehensive, regenerative strategy that integrates pharmacologic, biologic, and mechanical interventions in a single sequence. Daily low-dose tadalafil improves cavernosal oxygenation and arterial inflow, counteracting hypoxia-driven fibrosis. Tunneling injections of biologics deliver growth factors directly into and around the plaque, promoting regeneration and remodeling, while traction therapy provides continuous mechanotransductive stimulation for structural realignment. Together, these components act synergistically to modulate inflammation, restore microvascular perfusion, and induce tissue regeneration. Importantly, this work provides, to our knowledge, the first fully specified, step-by-step description of a Peyronie’s disease management protocol, enabling reproducible clinical implementation and facilitating meaningful comparison across future studies employing different biologic agents. Prospective randomized studies examining the efficacy of the 3Ts Protocol are needed. If so, the 3Ts Protocol represents a paradigm shift from deformity correction to structural restoration, offering a novel pathway toward multimodal management of Peyronie’s disease.
DG Hatzichristou (Thu,) studied this question.